Abstract OBJECTIVE: To study the clinical significance of FMS-like tyrosine kinase 3 (FLT3) mutations including internal tandem duplication (ITD) mutation and point mutation of tyrosine kinase domain (TKD) in children with acute myeloid leukemia (AML). METHODS: Bone marrow samples from 116 children with newly-diagnosed AML were obtained．Gene mutations of FLT3/ITD and FLT3/TKD were detected by RT-PCR. The relationship of FLT3 gene mutations with the clinical characteristics and the therapeutic efficacy was observed. RESULTS: FLT3/ITD and FLT3/TKD mutations were detected in 9 cases (7.8%) and 13 cases (11.2%) respectively out of the 116 children. FLT3/ITD mutations were observed in 3 cases of AML-M3 (3/9; 33.3%) and in 3 cases of AML-M5 (3/9; 33.3%). FLT3/TKD mutations were the most common in AML-M3 patients (10/13; 76.9%). The patients with FLT3/ITD mutations had a significantly higher peripheral WBC count and marrow blast percentage compared with the patients without FLT3/ITD mutations at diagnosis (P<0.01). The 3-year overall survival rate in patients with FLT3/ITD mutations was significantly lower than that in patients without FLT3/ITD mutations (38.9% vs 64.3%; P<0.05).ConclusionsFLT3/TKD mutations are common in children with AML-M3. The AML children with FLT3/ITD mutations present a high peripheral WBC count and a high marrow blast percentage at diagnosis and have an unfavorable outcome.
RUAN Min,WANG Ya-Qin,ZHANG Li et al. FLT3 mutations in children with acute myeloid leukemia: a single center study[J]. 中国当代儿科杂志, 2011, 13(11): 863-866.
RUAN Min,WANG Ya-Qin,ZHANG Li et al. FLT3 mutations in children with acute myeloid leukemia: a single center study[J]. CJCP, 2011, 13(11): 863-866.
［2］Thomton KA, Levis M. Images in clinical medicine. FLT3 mutation and acute myelogenous leukemia with leukostasis［J］. N Engl J Med, 2007, 357(16): 1639.
［3］Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay［J］. J Mol Diagn, 2003, 5(2): 96-102.
［5］Zhang L, Zhu X, Zou Y, Chen Y, Chen X. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China［J］. Int J Hematol, 2011, 93(2): 199-205.
［9］Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al.Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia［J］. Blood, 2001, 97(1): 89-94.
［10］Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implications of FLT3 mutations in pediatric AML［J］. Blood, 2006, 108(12): 36543661.
［11］Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia(AML)adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials［J］. Blood, 2001, 98(6): 1752-1759.
［13］Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients［J］. Blood, 2008, 111(5): 2527-2537.
［14］Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?［J］. Blood,2007,109(2):431-448.
